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Abstract
Rationale There is an ongoing discussion on the relation
between risk of violent behaviour and the use of antidepres-
sants. The claim that the use of antidepressants can cause
violent behaviour would gain credibility if a positive asso-
ciation between the two could be established.
Objective The objective of this study is to evaluate the
relationship between homicide, suicide and homicide–sui-
cide rates and the rates of antidepressant use by gender and
age group.
Method Nationwide data from the Netherlands on antide-
pressant prescriptions (ADs, SSRI and venlafaxine) and
lethal violence were analysed over the 15-year period from
1994 to 2008.
Results The findings indicated a significant negative asso-
ciation between lethal violence (homicide and suicide) and
prescription of antidepressants in the Netherlands, indicat-
ing that in a period in which the exposure of the Dutch
population to antidepressants increased, rates of lethal vio-
lence decreased.
Conclusions These data lend no support for an important
role of antidepressant use in lethal violence.
Keywords Epidemiology . Antidepressants . SSRI .
Suicide . Homicide . Lethal violence
Introduction
In recent years several publications have suggested a link
between the use of antidepressants (ADs)—more specifical-
ly SSRIs—and lethal violence including homicide, suicide
and homicide–suicide. In case reports and in the lay media,
it is frequently suggested that antidepressants can cause
serious adverse events, including suicide and violent crime.
If this is true, it is important to wage the risk of these
possible adverse events against the possible benefits of the
treatment with antidepressants. If, however, antidepressant
treatment is wrongfully associated with such serious adverse
events, these suggestions might lead to a situation in which
patients with an indication for treatment with an antidepres-
sant abstain from treatment because of fear for the possibility
of these adverse events.
Suicide
Previous studies on the relation between suicide rates
and the prescription of antidepressant data in the USA
and in the Nordic countries have shown a decline in
suicide rate over a period in which antidepressant sales
rose markedly (Grunebaum et al. 2004; Reseland et al.
2006). However, there is an ongoing discussion on the rela-
tion between suicide risk and the use of antidepressants in
children and adolescents. Although in clinical trials with
antidepressants in these groups no or very few completed
suicides are reported, there appears to be an increased risk for
suicidal ideation and suicidal behaviour (Hammad et al. 2006;
Barbui et al. 2009; Stone et al. 2009). This increased risk
seems to be present only in participants under 25. In adults
aged 25–64, there is a neutral effect and there seems to be a
reduced risk of suicidality and suicidal behaviour in those
aged over 64 (Stone et al. 2009).
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Homicide and homicide–suicide
Quantitative data on the relationship between violent
crime and antidepressants are scarce. One report on
homicide–suicides in New York over the years 1990–
1998 found that only 3 out of 127 (2.4%) homicide–
suicide perpetrators who were tested post-mortem for
the presence of an antidepressant tested positive. These
data “lend no support to the position that the use of
SSRIs is associated with violence or suicide” (Tardiff et
al. 2002). Another study on data collected in four US
states in the years 2001–2002 showed 15% positive
tests in homicide–suicide perpetrators and 19% positive
tests on antidepressants in suicide decedents. The authors
conclude that these results indicate that there is no link be-
tween pharmacotherapy and violent behaviour (Barber et al.
2008).
Other quantitative studies, however, do find signifi-
cant links between pharmacotherapy and criminal be-
haviour. For example, crime trends and prescription
rates of psycho-pharmaceuticals in the USA over the
years 1997–2004 were found to be associated: a rise
in the use of antidepressants and stimulants was associ-
ated with lower crime rates (Marcotte and Markowitz
2009). A recent study reported on the disproportionally high
number of reported violence in the FDA Adverse Event
Reporting System for antidepressants with serotonergic
effects (Moore et al. 2011).
In other qualitative publications, cases are presented
in which a person is using an antidepressant and com-
mits a violent crime. Defendants from the USA, UK,
Australia and the Netherlands suggested that antidepres-
sants were to blame for crimes committed (Healy et al.
2006; Mason 2002; Merckelbach et al. 2009) The claim
in court that the crime would not have been committed
if the antidepressant had not been used is called a
counterfactual (Höfler 2005). In other words if the ex-
posure to the antidepressant had not taken place, the
incident would not have happened. Here, the exposure
to the antidepressant is considered to be a causal factor
for the crime to take place. From an epidemiological
point of view, “[…] the decisive question is whether the
frequency of the undesirable event B will be influenced
by a change in the environmental factor A” (Hill 1965).
The claim that the use of antidepressants can cause
violent behaviour such as homicide would gain credi-
bility if a positive association between the two could be
established.
To answer this question, we undertook an epidemiologi-
cal study in the Netherlands on the use of antidepressants
and the rates of homicide, suicide and homicide–suicide in
the period 1994–2008. We conducted separate analyses
by gender and age group because of the well-known
differences between men and women with respect to these
forms of violent behaviour and the fact that earlier research
suggests that there may be differences between age groups
(Stone et al. 2009).
Methodology
Data
Various data sources have been used in this study. Data on
antidepressant prescriptions come from the GIP, an infor-
mation system of the Health Care Insurance Board, and is
available for the period 1994–2008. It contains information
on prescription drugs prescribed by general practitioners and
specialists, dispensed by pharmacists, general practitioners
and other outlets and are reimbursed under the Health Care
Insurance Act. The GIP databases contain data from a
representative sample of more than 12 million people (three
fourths of the Dutch population). The sample has been
obtained from 18 health insurance organisations and has
been extrapolated to the size of the entire Dutch population.
Detailed GIP data per type of antidepressant [total antide-
pressants (AD), SSRI and venlafaxine (Ve)] per age category
and gender were, however, only available for the period
2002–2008. In order to calculate the total number of users
per type of antidepressant group by gender and age group for
the period 1996–2001, we measured the average fraction of
users per antidepressant by gender and age group for the
period 2002–2008. In this time period (2002–2008), the frac-
tion of users by gender and age remained stable (AD: males
15–30—0.03, males 30–60—0.23, males 60+—0.09; females
15–30—0.06, females 30–60—0.39, females 60+—0.21;
SSRI: males 15–30—0.03, males 30–60—0.23, males
60+—0.08; females 15–30—0.07, females 30–60—0.42,
females 60+—0.18; Ve: males 15–30—0.03, males 30–60—
0.27, males 60+—0.64; females 15–30—0.07, females 30–
60—0.42, females 60+—0.14). Subsequently, we applied the
fraction of users per antidepressant by gender and group to the
period 1996–2001 to calculate the total number of users by
gender and age group, to allow for the calculation of user rates
per 100,000.
Homicide data were collected from the Dutch Homicide
Monitor, an ongoing data collection effort that includes the
characteristics of incidents, victims and perpetrators of all
homicide cases in the Netherlands from 1992 onwards
(Nieuwbeerta 2007). Homicide was defined as a lethal of-
fence which has been categorized as either murder (art. 289
and 291 Dutch Code of Criminal Law) or manslaughter (art.
287, 288 and 290 Dutch Code of Criminal Law). The
information in this data set is based on various sources,
which partially overlap and complement each other and
include the following: homicide-related articles generated
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by the Netherlands National News Agency (ANP), annual
summaries of homicides from Elsevier (a weekly magazine),
files from the National Bureau of Investigation (NRI), the
Public Prosecution Office, the Judicial Information Service,
the Ministry of Justice and the Criminal Justice Knowledge
Centre (WODC).
Data on homicide—suicide events were also obtained
from the Dutch Homicide Monitor and supplemented with
additional information stemming from newspaper articles. A
homicide—suicide involved a homicide followed by the
suicide of the perpetrator within 1 week of the preceding
homicide.
Suicide data were retrieved from the dataset Causes of
Death Statistics from the Dutch Central Bureau of Statistics,
Statistics Netherlands (CBS). For the overall population,
suicide data were available for the period 1994–2008. For
subpopulations by gender and age, data were available from
1996 onwards. There have been no changes in the way
suicides were reported in the Netherlands since 1996.
Cases were classified as suicides based on the cause of
death given in the certificates from the doctor or forensic
pathologist (ICD-10 codes X60-X84). Such officially reported
mortality data are considered reasonably sound (Móscicki
1997). Undetermined deaths are not included in the CBS
dataset. Not including undetermined deaths leads to underes-
timation and including leads to overestimation of suicide rates.
For the purpose of this study, changes over time are important.
The above-mentioned data sets are described in more detail
elsewhere (Liem 2010).
Analysis
Multiple linear regression was used to examine the associ-
ation between the dependent variables homicide, suicide and
homicide–suicide rates and the independent variables of
antidepressant use. Antidepressant use was split into three
variables: The total use of antidepressants (AD), the total
use of SSRIs (SSRI) and the total use of SSRIs including
venlafaxine (SSRI+Ve). The reason for combining the use of
SSRIs and venlafaxine is research suggesting that venlafax-
ine acts as an SSRI at 75 mg a day and as a dual 5-HT and
NE reuptake inhibitor at higher doses (225 and 375 mg a
day, Debonnel et al. 2007).
Total user rates and mortality rates were calculated based
on population figures for each year. Separate sets of regres-
sion analyses were conducted for each independent variable
(homicide rate, suicide rate and homicide–suicide rate). In
addition, we conducted analyses on six subgroups by age
and gender. Separate sets of regression analyses were con-
ducted per subgroup to determine the relation between an-
tidepressant use and lethal violence. Homicide rates for
males above 60 and females in all age categories are ex-
tremely low and therefore not reported. The same accounts
for the homicide–suicide rate by age and gender subcatego-
ries. Given its rare incidence, especially when disaggregated
by age and gender category, these subanalyses are not
reported (Liem et al. 2009). Statistical analyses were per-
formed with SPSS version 17.0.
Results
Our study encompassed nationwide data over a 15-year
period. In this period, the homicide rate per 100,000
remained fairly constant, with a moderate decline in recent
years, leading to an average of 160 homicide victims per
year. The suicide rate decreased steadily from 10.26 (ap-
proximately 1,500 victims) in 1994 to 8.77 (approximately
1,400 victims) per 100,000 in 2008. The homicide–suicide
rate remained relatively stable, averaging at 0.05 per
100,000 (varying from 4 to 14 victims per year, see
Fig. 1). In the same period, the rate of total antidepressant
use increased considerably, from 3,038.81 in 1994 to
5,650.58 per 100,000 in 2008. A similar increase was ob-
served for the rate of SSRI use alone, which more than
doubled from 1,482.25 in 1994 to 3,161.15 per 100,000 in
2008 as well as the rate of SSRI use including venlafaxine,
with an increase of 1,486.81 in 1994 to 3,904.20 per
100,000 in 2008. Over the same period, the number of
defined daily doses used rose from 59.6 million in 1994 to
245.3 million in 2008: a fourfold increase. This indicates
that not only more people used antidepressants, but also that
the mean duration or intensity of the treatment grew (Table 1
and Fig. 1).
Associations with rates of lethal violence
Linear regression analyses revealed that the total rate of
antidepressant use was negatively associated with both ho-
micide rates and suicide rates, but not with homicide–sui-
cide rates alone (see Table 2). Similar results were found
between the rates of SSRI use alone and homicide rates as
well as suicide rates. Rates of SSRI use and homicide–
suicide were not associated.
Rates of the use of SSRIs including venlafaxine were also
found to be negatively associated with both homicide rates
and suicide rates. No significant independent association
was found between rates of SSRIs including venlafaxine
and homicide–suicide.
Associations with rates of lethal violence by gender and age
Figure 2 reflects the relationship between total antidepres-
sant use (AD) and rates of lethal violence by gender and age
category. The results from the overall regression analyses
were replicated (see Table 2): In virtually all categories,
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there was a significant negative relationship reported
between antidepressant use and suicide, with the excep-
tion for males aged 30–60, where no relationship in
either direction was found. Similarly, there was either
a significant negative relationship between the rate of
antidepressant use and homicide rate (males aged 30–60)
or no significant relationship in either direction (males
aged 15–30).
The relationship between SSRI alone and rates of lethal
violence per subcategory displayed similar tendencies:
There was either a negative relationship between suicide
and SSRI alone, or no relationship in either direction (males
and females aged 30–60). SSRI use was negatively associ-
ated with the homicide rate (males aged 15–30 and males
aged 30–60). These results were replicated for SSRI includ-
ing venlafaxine (SSRI+Ve).
Discussion
Suicide
In the period under study, the suicide rate in the Netherlands
decreased from 10.26 in 1994 to 8.77 per 100,000 in 2008.
This decrease seems to be a continuation of a long-term
decline since the 1980s, in which the suicide rate was
approximately 15 per 100,000 (van Hemert and de Kruif
2009).
The increase in the use of antidepressants is associ-
ated with a decrease in suicide rate. The association is
strong; the changes in the use of antidepressants can
account for 54% of the variation in suicide rate. These
findings are in line with previous research. When ex-
amining the younger subgroups that might be especially
at risk, the negative association between prescription of
AD and SSRI ± Ve on the one hand and suicide rates on
the other is confirmed. The increase in suicide risk in
children and adolescents found in previous research is
largely based on an increase in suicidal ideation and
nonfatal suicidal behaviour in studies comparing effica-
cy of AD versus placebo (Hammad et al. 2006; Stone et
al. 2009). The risk factors for nonfatal suicidal behaviour
(e.g. younger and female) and completed suicide (e.g. older
and male) are not the same: An increase in suicidal ideation
and nonfatal suicidal behaviour does not necessarily reflect an
increase in completed suicide (Baldessarini et al. 2006).
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Table 1 Homicide, suicide and homicide–suicide rates per 100,000
and rates of antidepressant use in the Netherlands, 1996–2008 (95%
CI)
Homicide 1.28 (1.14–1.43)
Suicide 9.48 (9.20–9.76)
Homicide–suicide 0.05 (0.04–0.06)
AD 4,745.48 (4,183.68–5,307.28)
SSRI 2,791.73 (2,397.64–3,185.83)
SSRI+Ve 3,149.78 (2,663.89–3,717.67)
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Homicide and homicide–suicide
To our knowledge we are the first to report on the relation
between lethal violence directed towards others and the use
of antidepressants over a long period of time (15 years). We
found a significant negative association between homicide
and prescription of AD and SSRI ± Ve in the Netherlands,
indicating that in a period in which the exposure of the
Dutch population to antidepressants increased, the homicide
rates decreased. As is the case for suicide, the association is
strong, changes in the use of antidepressants can account for
65% of the variation in homicide rates. These data lend no
support for an important role of antidepressant use in homi-
cide. With regard to the subgroup analysis, the younger male
groups are of primary interest. Here, the same negative
associations are found.
Table 2 Multiple regression
analyses for homicide, suicide
and homicide–suicide rates per
100,000 and rates of antidepres-
sant use in the Netherlands,
1996–2008 (95% CI)
Regression coefficient P 95% CI R2
Total
Homicide AD 0.808 <0.001 1.83–2.71 0.653
SSRI 0.721 0.002 1.59–2.46 0.520
SSRI+Ve 0.785 0.001 1.63–2.31 0.617
Suicide AD 0.733 0.002 10.23–12.21 0.537
SSRI 0.669 0.006 9.90–11.72 0.448
SSRI+Ve 0.725 0.002 9.98–11.44 0.526
Homicide–suicide AD 0.288 0.298 0.02–0.13 0.083
SSRI 0.290 0.294 0.03–0.12 0.084
SSRI+Ve 0.271 0.328 0.03–0.11 0.074
Male 15–30
Homicide AD 0.587 0.021 8.70–15.47 0.344
SSRI 0.586 0.022 8.49–13.63 0.344
SSRI+Ve 0.645 0.009 8.81–13.18 0.416
Suicide AD 0.839 <0.001 13.51–19.08 0.704
SSRI 0.801 0.001 12.09–16.57 0.642
SSRI+Ve 0.831 <0.001 12.10–15.80 0.690
Male 30–60
Homicide AD 0.822 <0.001 4.60–6.59 0.676
SSRI 0.763 0.001 4.12–5.94 0.582
SSRI+Ve 0.833 <0.001 4.18–5.49 0.695
Suicide AD 0.381 0.199 11.58–18.92 0.145
SSRI 0.404 0.152 12.55–18.46 0.163
SSRI+Ve 0.354 0.235 13.50–18.64 0.126
Male 60+
Suicide AD 0.813 0.001 24.29–35.48 0.660
SSRI 0.707 0.005 21.45–32.89 0.500
SSRI+Ve 0.794 0.001 22.27–30.88 0.630
Female 15–30
Suicide AD 0.650 0.016 4.34–8.72 0.422
SSRI 0.595 0.025 4.01–7.74 0.354
SSRI+Ve 0.642 0.018 4.14–7.49 0.412
Female 30–60
Suicide AD 0.503 0.080 7.88–13.60 0.253
SSRI 0.413 0.142 7.53–12.43 0.170
SSRI+Ve 0.498 0.083 7.95–12.03 0.248
Female 60+
Suicide AD 0.867 >0.001 13.21–18.97 0.751
SSRI 0.815 >0.001 11.94–17.65 0.664
SSRI+Ve 0.841 >0.001 11.56–16.06 0.708
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Fig. 2 Rates of lethal violence per 100,000 and rates of antidepressant use in the Netherlands, 1996–2008 by gender and age categories
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These findings are in contrast with a recent study
based on reported adverse events in the Adverse Event
Reporting System of the FDA from 2004 to 2009,
which concludes that “acts of violence towards others
are a genuine and serious adverse drug event associated
with a relatively small group of drugs [including] anti-
depressants with serotonergic effects” (Moore et al.
2011). In this study, violent thoughts and acts towards
others were significantly more reported than would be
expected by chance. There are several ways to explain
these findings. Publicity about the possibility of violent
behaviour as an adverse event of a class of drugs will
raise the number of reports. In addition, one has to take
the reasons for prescribing antidepressants into account.
Despair can be one reason to consider such treatment.
At the same time, despair is a risk factor for violent
thoughts and behaviour. Further, problems with impulse
control may be a reason to consider antidepressant
treatment. Recently, the first placebo-controlled trial
was published in which efficacy was shown of an SSRI
(fluoxetine) in conjunction with cognitive behavioural
therapy in a group of perpetrators of domestic violence.
Measures of anger and physical aggression were re-
duced (George et al. 2011). These findings suggest that
antidepressant treatment might actually help patients to
control their violent thoughts and behaviour. Earlier
research has shown that aggressive behaviour both to
oneself or outwards to others is associated with seroto-
nergic dysfunction. Enhancement of serotonergic function
by prescription of an antidepressant might be an appro-
priate thing to do and explain of the negative associa-
tions found in the present study (Walsh and Dinan
2001).
There appears to be a striking parallel with the use
of antidepressants and suicide. However, suicide has a
more direct relationship with depression and the use of
antidepressants than homicide. Antidepressants are not
generally prescribed to homicidal persons. The negative
association found between the use of antidepressants
and homicide is probably more strongly influenced by
other factors.
Limitations
Detailed information on individuals who committed a form
of lethal violence was not available. Future research should
attempt to overcome this difficulty by obtaining additional
information on autopsy reports from suicide decedents, an
approach used in previous studies (Barber et al. 2008). In
addition, detailed data per type of antidepressant per age and
gender category were only available for the period 2002–
2008. By applying average fractions of users per antidepres-
sants, we were able to calculate the total number of users
by gender and age group for the period 1996–2001. This
approach, however, is based on the assumption that the frac-
tion of users per antidepressants remains fairly stable over
time. This assumption might have caused a wrongful estima-
tion of actual use per age and gender category.
Conclusion
Despite these limitations, this study relies on nationwide
data and is the first to report on the relation between
different forms of lethal violence and the use of anti-
depressants over long period of time. The findings for
homicide and suicide appear to have much in common.
However, violent acts such as homicide, suicide and
homicide–suicide are complex forms of human behaviour
in which many factors may play a role (Luo et al. 2011).
Medication is only one of them. One should be cautious to
draw simple conclusions. The associations found point to a
beneficial effect of antidepressants on these very serious forms
of aggression.
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